Investigational drug · Phase 3
Crenolanib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Newly Diagnosed FLT3 Mutated AML, Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
22
Any phase or sponsor naming "Crenolanib"
First trial start
2018
Aug 15, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Crenolanib", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Newly Diagnosed FLT3 Mutated AML
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Crenolanib" as an intervention, largest first.
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLPivotal-lookingCompleted
Arog Pharmaceuticals, Inc.Industry
NCT03258931 · 214 participants · Start Aug 15, 2018 · Primary completion Apr 6, 2026
Drug: Crenolanib; Midostaurin and 2 more · For: Newly Diagnosed FLT3 Mutated AML
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 31 sites in all
- Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTPivotal-lookingStatus unknown
Arog Pharmaceuticals, Inc.Industry
NCT02847429 · 120 participants (planned) · Start Aug 2016 · Primary completion Aug 2021
Drug: Crenolanib; Placebo · For: GIST With D842V Mutated PDGFRA Gene
Sites: Santa Monica, California; Miami, Florida; Durham, North Carolina · 23 sites in all
- Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AMLPivotal-lookingCompleted
Arog Pharmaceuticals, Inc.Industry
NCT03250338 · 106 participants · Start Aug 16, 2018 · Primary completion Apr 3, 2026
Drug: Crenolanib; Cytarabine and 5 more · For: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Sites: Sacramento, California; Gainesville, Florida; Chicago, Illinois · 62 sites in all
Arog Pharmaceuticals, Inc.Industry
NCT01657682 · 56 participants · Start Oct 2012 · Primary completion Apr 2019
Drug: Crenolanib besylate · For: Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Sites: Houston, Texas
St. Jude Children's Research HospitalAcademic, hospital or other
NCT01393912 · 55 participants · Start Jul 2011 · Primary completion Sep 2014
Drug: Crenolanib · For: Diffuse Intrinsic Pontine Glioma; Progressive or Refractory High-Grade Glioma
Sites: Memphis, Tennessee
- CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid TumorsCompleted
Arog Pharmaceuticals, Inc.Industry
NCT00949624 · 50 participants · Start Dec 2005 · Primary completion Jun 2008
Drug: CP-868,596; Docetaxel and 7 more · For: Advanced Solid Tumors
Sites: Durham, North Carolina; East Melbourne, Australia
Aptose Biosciences Inc.Industry
NCT04477291 · 45 participants · Start Oct 6, 2020 · Primary completion Apr 15, 2024
Drug: CG-806 · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Sites: Duarte, California; Los Angeles, California; Miami, Florida · 10 sites in all
Arog Pharmaceuticals, Inc.Industry
NCT02283177 · 44 participants · Start Jan 2015 · Primary completion Dec 2019
Drug: crenolanib; cytarabine and 2 more · For: Newly Diagnosed AML With FLT3 Activating Mutations
Sites: Duarte, California; Iowa City, Iowa; Boston, Massachusetts · 9 sites in all
Arog Pharmaceuticals, Inc.Industry
NCT02400255 · 30 participants · Start Sep 2015 · Primary completion May 2022
Drug: Crenolanib besylate · For: Acute Myeloid Leukemia
Sites: Houston, Texas
- Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric AdenocarcinomaCompleted
Arog Pharmaceuticals, Inc.Industry
NCT03193918 · 30 participants · Start Apr 14, 2017 · Primary completion Jul 15, 2020
Drug: Crenolanib; Ramucirumab and 1 more · For: Esophagogastric Adenocarcinoma
Sites: New York, New York
Newest research
PubMed records naming it or its code names, newest first.
- Recent advances in the treatment of FLT3-mutated acute myeloid leukemia.
Koh JS, Song IC · Blood Res 2026
- Medicinal Insights Into FLT3 Inhibitors as Anticancer Agents: Current Status and Future Direction.
Kumar A, Kumari P, Paudel KR, et al. · Arch Pharm (Weinheim) 2026
- Disruption of gastrointestinal PDGFRα+ cells leads to loss of postjunctional inhibitory motor responses.
Hwang SJ, Sanders KM, Ward SM · Am J Physiol Gastrointest Liver Physiol 2026
- Developing and validating a sensitive and fast UPLC-MS/MS method for estimating the in vitro metabolic stability of crenolanib in HLMs: identification of structural alarms related to the in silico toxicity and metabolic lability.
Attwa MW, Ali AM, AlRabiah H, et al. · Anal Methods 2025
- Cephalomannine as in vitro and in vivo anticancer agent in mesothelioma cells: mechanisms of action.
Morani F, Dell'Anno I, Daga A, et al. · BMC Cancer 2025
- Selective EV Protein Sorting and Pathway Perturbation in AML Upon Synergistic FLT3 and Hedgehog Pathway Inhibition.
Blöchl C, Blümel G, Wolf M, et al. · J Extracell Vesicles 2025
Also in development for Newly Diagnosed FLT3 Mutated AML
- DuanorubicinPhase 31 trial
Arog Pharmaceuticals, Inc. · Newly Diagnosed FLT3 Mutated AML
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.